1) Strategic Focus and Leadership Changes
- Edwards Lifesciences is committed to a patient-centered innovation strategy, emphasizing sustainable performance and growth in structural heart therapies.
- The company welcomed Doretta Mistras as CFO, highlighting her immediate impact on the team.
- Leadership remains focused on transforming care in structural heart disease through innovation and evidence generation.

2) Financial Performance and Segment Results
- Q2 2026 total sales reached $1.74 billion, a 12.5% YoY increase.
- Adjusted EPS for the quarter was $0.78, with a reaffirmed full-year EPS guidance of $2.95 to $3.05.
- TAVR sales were $1.3 billion, up 10.5% YoY, driven by strong procedural growth and SAPIEN platform differentiation.
- TMTT sales increased 44.8% YoY to $195.9 million, with significant contributions from PASCAL, EVOQUE, and SAPIEN M3.
- Surgical segment sales were $284 million, reflecting a 5% YoY increase.

3) Challenges and Headwinds
- The company anticipates challenges in the second half of 2026 due to high comps from the previous year, which may artificially lower growth rates.
- Foreign exchange impacts are expected to be a headwind, with a projected $35 million impact in the second half.
- Changes in California law affecting R&D tax credits may also influence financial performance.

4) Operational and Product Developments
- Edwards is focused on expanding its TAVR, TMTT, and Surgical portfolios, with several key product launches and approvals expected in the coming months.
- Upcoming milestones include the finalization of the U.S. TAVR NCD and the launch of next-generation PASCAL technology.
- The company aims for TMTT revenue to reach $2 billion by 2030, supported by ongoing product adoption and new indications.

5) Guidance and Outlook
- The full-year sales growth guidance has been increased to 10% to 11%, with TAVR growth guidance raised to 8% to 9%.
- The company expects to maintain its long-term target of 10% average sales growth and operating margin expansion.
- The call did not provide specific details on the PROGRESS trial results or their potential impact on TAVR adoption, which may be critical for future growth.

Bottom line: Edwards Lifesciences is positioned for sustainable growth driven by strong performance across its product segments and strategic leadership. The company’s focus on innovation and evidence generation, coupled with increased guidance for 2026, reinforces confidence in achieving long-term growth targets, despite anticipated short-term headwinds.